Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Cytokinetics Inc is a biotechnology business based in the US. Cytokinetics shares (CYTK) are listed on the NASDAQ and all prices are listed in US Dollars. Cytokinetics employs 253 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $47.25 |
|---|---|
| 52-week range | $17.72 - $48.10 |
| 50-day moving average | $39.68 |
| 200-day moving average | $37.57 |
| Wall St. target price | $61.58 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.21 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $47.25 from 2022-06-24
| 1 week (2022-06-17) | 16.44% |
|---|---|
| 1 month (2022-05-27) | 12.85% |
| 3 months (2022-03-25) | 29.56% |
| 6 months (2021-12-27) | 3.05% |
| 1 year (2021-06-25) | 110.00% |
|---|---|
| 2 years (2020-06-26) | 98.78% |
| 3 years (2019-06-27) | 326.83% |
| 5 years (2017-06-27) | 253.93% |
| Revenue TTM | $65 million |
|---|---|
| Gross profit TTM | $-89,510,000 |
| Return on assets TTM | -19.5% |
| Return on equity TTM | -279.9% |
| Profit margin | 0% |
| Book value | $1.36 |
| Market capitalisation | $4 billion |
TTM: trailing 12 months
We're not expecting Cytokinetics to pay a dividend over the next 12 months.
Cytokinetics's shares were split on a 1:6 basis on 24 June 2013. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytokinetics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cytokinetics shares which in turn could have impacted Cytokinetics's share price.
Over the last 12 months, Cytokinetics's shares have ranged in value from as little as $17.72 up to $48.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytokinetics's is 1.2246. This would suggest that Cytokinetics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.